LC
GLMD icon

Lindbrook Capital’s Galmed Pharmaceuticals GLMD Stock Holding History

Lindbrook Capital’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-64
Closed -$21K – 2527
2021
Q4 		$21K Buy
+64
New +$28.9K ﹤0.01% 995

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return

Lindbrook Capital's GLMD Position: Q1 2022 in Review

Lindbrook Capital sold out of Galmed Pharmaceuticals (GLMD) in Q1 2022, closing a stake of 64 shares — an estimated $21K sold.

Lindbrook Capital first reported a position in GLMD in Q4 2021 and held it in 1 quarter. The position peaked at $21K in Q4 2021. 23 funds tracked by Wall St. Rank hold GLMD as of Q1 2022.

  • Lindbrook Capital reported no remaining Galmed Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Lindbrook Capital sold 64 Galmed Pharmaceuticals shares in Q1 2022, an estimated $21K.
  • Lindbrook Capital first reported a position in Galmed Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Lindbrook Capital's Galmed Pharmaceuticals position peaked at $21K in Q4 2021.
  • 23 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2022.

Based on Lindbrook Capital's 13F filing for Q1 2022, filed 21 Apr 2022.